SEARCH:   Advanced

Blood, 15 May 2004, Vol. 103, No. 10, pp. 3773-3776. Prepublished online as a Blood First Edition Paper on January 22, 2004; DOI 10.1182/blood-2003-10-3422. This Article Full Text (PDF) All Versions of this Article: 2003-10-3422v1 103/10/3773    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Eichinger, S. Articles by Kyrle, P. A Search for Related Content PubMed PubMed Citation Articles by Eichinger, S. Articles by Kyrle, P. A Social Bookmarking                   What's this? Submitted October 8, 2003 Accepted January 5, 2004 Thrombin activatable fibrinolysis inhibitor (TAFI) and the risk of recurrent venous thromboembolism Sabine Eichinger*, Verena Schoenauer, Ansgar Weltermann, Erich Minar, Christine Bialonzcyk, Mirko Hirschl, Barbara Schneider, Peter Quehenberger, and Paul A Kyrle Dept. of Internal Medicine I, Div. of Hematology/Hemostasis, University of Vienna, Vienna, Austria; Ludwig-Boltzmann Institute for Thrombosis Research, University of Vienna, Vienna, Austria Dept. of Internal Medicine I, Div. of Hematology/Hemostasis, University of Vienna, Vienna, Austria Dept. of Internal Medicine II, Div. of Angiology, University of Vienna, Vienna, Austria Dept. of Dermatology, Wilhelminenspital, Vienna, Austria Dept. of Angiology, Hanuschkrankenhaus, Vienna, Austria Institute of Medical Statistics, University of Vienna, Vienna, Austria Clinical Institute of Chemical and Laboratory Diagnostics, University of Vienna, Vienna, Austria * Corresponding author; email: sabine.eichinger{at}akh-wien.ac.at. The impact of fibrinolysis for predicting the risk of recurrent venous thromboembolism (VTE) is low. We prospectively followed 600 patients with a first VTE, and evaluated the thrombin activatable fibrinolysis inhibitor (TAFI) as a risk factor of recurrence. A high TAFI ( 75th percentile of thrombosis patients) was associated with a 2-fold higher risk of recurrence compared with lower levels. The probability of recurrence two years after anticoagulation was 14.5% (95% CI 8.6%-20.4%) among patients with high TAFI and 6.8% (95% CI 4.3%-9.3%) among patients with lower levels (p=0.006). Our data also support the concept of a linkage between fibrinolysis and the coagulation system. Patients with high TAFI had significantly higher levels of factors XI, VIII and IX, and a high risk of recurrence was seen among patients with high TAFI and high levels of one of these factors. The relative risk (RR) of recurrence was highest among patients with high TAFI and high factor XI (2.9; 95% CI 1.3-6.9), high factor VIII (RR 6.5; 95% CI 2.9-14.8), or high factor IX (RR 2.0, 95% CI 1.0-3.9), compared with patients with low levels of TAFI and one of these factors. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. E. Meltzer, C. J.M. Doggen, P. G. de Groot, J. C.M. Meijers, F. R. Rosendaal, and T. Lisman Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men Haematologica, June 1, 2009; 94(6): 811 - 818. [Abstract] [Full Text] [PDF] C. Erem, M. Kocak, I. Nuhoglu, M. Yilmaz, and O. Ucuncu Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism Eur. J. Endocrinol., May 1, 2009; 160(5): 863 - 868. [Abstract] [Full Text] [PDF] J. Verdu, P. Marco, S. Benlloch, and J. Lucas Association Between the Thr325Ile and Ala147Thr Polymorphisms of the TAFI Gene and the Risk of Venous Thromboembolic Disease Clinical and Applied Thrombosis/Hemostasis, October 1, 2008; 14(4): 494 - 495. [PDF] M. B. Boffa, D. Maret, J. D. Hamill, N. Bastajian, P. Crainich, N. S. Jenny, Z. Tang, E. M. Macy, R. P. Tracy, R. F. Franco, et al. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis Blood, January 1, 2008; 111(1): 183 - 189. [Abstract] [Full Text] [PDF] L. O. Mosnier and B. N. Bouma Regulation of Fibrinolysis by Thrombin Activatable Fibrinolysis Inhibitor, an Unstable Carboxypeptidase B That Unites the Pathways of Coagulation and Fibrinolysis Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2445 - 2453. [Abstract] [Full Text] [PDF] B. Jilma, F. M. Kovar, G. Hron, G. Endler, C. L. Marsik, S. Eichinger, and P. A. Kyrle Homozygosity in the Single Nucleotide Polymorphism Ser128Arg in the E-Selectin Gene Associated With Recurrent Venous Thromboembolism. Arch Intern Med, August 14, 2006; 166(15): 1655 - 1659. [Abstract] [Full Text] [PDF] J. L. Arolas, S. Bronsoms, S. Ventura, F. X. Aviles, and J. J. Calvete Characterizing the Tick Carboxypeptidase Inhibitor: MOLECULAR BASIS FOR ITS TWO-DOMAIN NATURE J. Biol. Chem., August 11, 2006; 281(32): 22906 - 22916. [Abstract] [Full Text] [PDF] E. Ceresa, E. Brouwers, M. Peeters, C. Jern, P. J. Declerck, and A. Gils Development of ELISAs Measuring the Extent of TAFI Activation Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 423 - 428. [Abstract] [Full Text] [PDF] J. L. Arolas, J. Lorenzo, A. Rovira, J. Castella, F. X. Aviles, and C. P. Sommerhoff A Carboxypeptidase Inhibitor from the Tick Rhipicephalus bursa: ISOLATION, cDNA CLONING, RECOMBINANT EXPRESSION, AND CHARACTERIZATION J. Biol. Chem., February 4, 2005; 280(5): 3441 - 3448. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020